Advance in research on the relationship between mTOR signaling pathway and tumors

Journal of Xi'an Jiaotong University (Medical Sciences)

Volumn 31, Issue 1, 2010, Pages 1-9

  Zheng, Peng Sheng ^a   Ji, Jing ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

mTOR inhibitor; mTOR signaling pathway; Rapamycin; Tumor therapy

Indexed keywords

DEFOROLIMUS; EVEROLIMUS; FLUOROURACIL; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TEMSIROLIMUS;

ANGIOGENESIS; CANCER INHIBITION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; ENZYME ACTIVITY; MAMMAL CELL; NONHUMAN; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION;

EID: 75749155907     PISSN: 16718259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. HEITMAN J, MOVVA NR, HALLI MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast [J]. Scinece, 1991, 253(5022):905-909.
2. ANDRADE MA, BORK P. HEAT repeats in the Huntington's disease protein [J]. Nat Genet, 1995, 11(2):115-116.
3. JACINTO E, HALL MN. TOR signaling in bugs, brain and brawn [J]. Nat Rev Mol Cell Biol, 2003, 4(2):117-126.
4. PETERSON RT, PETER AB, MICHAEL JC, et al. FKBP-12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions [J]. J Biol Chem, 2000, 275(10):7416-7423.
5. HARA K, MARUKI Y, Long X, et al. Raptor, a binding partner of targer of rapamycin (TOR), mediates TOR action [J]. Cell, 2002, 110:177-189.
6. KIM DH, SARBASSOV DD, ALI SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery [J]. Cell, 2002, 110(2):163-175.
7. SARBASSOV DD, ALI SM, KIM DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton [J]. Curr Biol, 2004, 14(14):1296-1302.
8. VIGNOT S, FAIVRE S, AGUIRRE D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives [J]. Annals of Oncology, 2005, 16:525-537.
9. ADJEI AA, HIDALGO M. Intracellular signal transduction pathway proteins as targets for cancer therapy [J]. J Clin Oncol, 2005, 23:5386-5403.
10. HAY N, SONENBERG N. Upstream and downstream of mTOR [J]. Genes & Development, 2004, 18:1926-1945.
11. RUTTER GA, SILVA XAVIER GD, LECLERC I. Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis [J]. Biochem J, 2003, 375:1-16.
12. INOKI K, ZHU T, GUAN KL. TSC2 mediates cellular energy response to control cell growth and survival [J]. Cell, 2003, 115:577-590.
13. CHENG SW, FRYER LG, CARLING D, et al. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status [J]. J Biol Chem, 2004, 279:15719-15722.
14. HEESOM KJ, DENTON RM. Dissociation of the eukaryotic initiation factor-4E/4E-BP1 complex involves phosphorylation of 4E-BP1 by an mTOR-associated kinase [J]. FEBS Lett, 1999, 457:489-493.
15. HARA K, YONEZAWA K, WENG QP, et al. Amino acid sufficiency and mTOR regulate P70 S6 kinase and eIF-4E BP1 through a common effector mechanism [J]. J Biol Chem, 1998, 273:14484-14494.
16. CHOE G, HORVATH S, CLOUGHESY TF, et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathyway in glioblastoma patients in vivo [J]. Cancer Res, 2003, 63:2742-2746.
17. NEVE RM, HORVATH S, HYNES NE. Distinct roles for phosphoinostide 3-kinase, mitogen activated protein kinase and P38 MAPK in mediating cell cycle progression of breast cancer cells [J]. Oncogene, 2002, 21:4567-4576.
18. PHILP AJ, CAMPBELL IG, LEET C, et al. The phosphatidylinositol 3-kinase p85 alpha gene is an oncogene in human ovarian and colon tumors [J]. Cancer Res, 2001, 61:7426-7429.
19. KOZMA SC, THOMAS G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K [J]. Bioassays, 2002, 24:65-71.
20. CANTLEY LC, NEEL BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining thephosphoinositide 3-kinase/AKT pathway [J]. Proc Natl Acad Sci USA, 1999, 96(8):4240-4245.
21. DOWNWARD J. Targeting RAS signalling pathways in cancer-therapy [J]. Nat Rev Cancer, 2003, 3(1):11-22.
22. SCHULZE WX, DENG L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family [J]. Mol Syst Biol, 2005, 1(1):2005-2008.
23. CHEUNG TH, LO KW, YIM SF, et al. Epigenetic and genetic alternation of PTEN in cervical neoplasm [J]. Gynecol Oncol, 2004, 93:621-627.
24. SAWYERS CL. Will mTOR inhibitors make it as cancer drugs [J]? Cancer Cell, 2003, 4:343-348.
25. MASSION PP, TAFLAN PM, SHYUR Y, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression [J]. Am J Respir Crit Care Med, 2004, 170:1088-1094.
26. WEST KA, BROGNARD J, CLARK AS, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells [J]. J Clin Invest, 2003;111:81-90.
27. LIAO Y, GROBHOLZ R, ABEL U, et al. Increase of AKT/PKB expression correlates with Gleason pattern in human prostate cancer [J]. Int J Cancer, 2003, 107:676-680.
28. WANG S, GAO J, LEI Q, et al. Prostate-specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer [J]. Cancer Cell, 2003, 4:209-221.
29. BACKMAN SA, GHAZARIAN D, SO K, et al. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten [J]. Proc Natl Acad Sci USA, 2004, 101:1725-1730.
30. BOSE S, CHANDRAN S, MIROCHA JM, et al. The Akt pathway in human breast cancer: a tissue-array-based analysis [J]. Mod Pathol, 2006, 19:238-245.
31. YILMAZ OH, VALDEZ R, THEISEN BK, et al. PTEN dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells [J]. Nature, 2006, 441:418-9.
32. STOYANOVA R, CLAPPER ML, BELLACOSA A, et al. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations [J]. Cancer Biol Ther, 2004, 3:1313-1321.
33. UEGAKI K, KANAMOTI Y, KIGAMWA J, et al. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma [J]. Oncol Rep, 2005, 14:389-392.
34. SOLIMAN PT, SCHMELER KM, BROADDUS RR, et al. mTOR inhibition as a potential treatment for progesterone refractory endometrial hyperplasia [J]. J Clin Oncol, 2005, 23:5080-5081.
35. MUTTER GL, LIN MC, FITZGERALD JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precarcinomas [J]. J Natl Carcinoma Inst, 2000, 92:924-931.
36. CHAKRAVARTI A, ZHAI G, SUZUKI Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas [J]. J Clin Oncol, 2004, 22:1926-1933.
37. FAIVRE S, KROEMER G, RAUMOND E. Current development of mTOR inhibitors as anticancer agents [J]. Nat Rev Drug Discov, 2006, 5:671-688.
38. TELL G, PINES A, ARTUSI F, et al. Control of phosphatase and tensin homolog (PTEN) gene expression in normal and neoplastic thyroid cells [J]. Endocrinology, 2004, 145:4660-4666.
39. KANG YH, LEE HS, KIM WH. Promoter methylation and silencing of PTEN in gastric carcinoma [J]. Lab Invest, 2002, 82(3):285-291.
40. GUBA M, REITENBUCH PV, STEINBAUER M, et al. Rapamycin inhibitsprimary and metastatic tumor growth by antiangiogenesis involvement of vascular endothelial growth factor [J]. Nature Medicine, 2002, 8(4):128-135.
41. MOHACSI PJ, TULLER D, HULLIGER B, et al. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor [J]. J Heart Lung Transplant, 1997, 16:484-492.
42. MARKUS G, GUDRUN EK, EVELYN N, et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer [J]. Transplant International, 2005, 18(1):89-94.
43. BRAZELTON TR, MORRIS RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs [J]. Curr Opin Immunol, 1996, 8(5):710-720.
44. HUDSON CC, LIU M, CHIANG GG, et al. Regulation of hypoxia-inducible factor1 alpha expression and function by the mammalian target of rapamycin [J]. Mol Cell Biol, 2002, 22(20):7004-7014.
45. HUMAR R, KIEFER FN, BERNS H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling [J]. FASEB J, 2002, 16:771-780.
46. MIRSHAHI P, TOPRAK SK, FAUSSAT AM, et al. Malignant hematopoietic cells induce an increased expression of VEGFR-1 and VEGFR-3 on bone marrow endothelial cells via AKT and mTOR signalling pathways [J]. Biochem Biophys Res Commun, 2006, 349(3):1003-1010.
47. WEPPLER SA, KRAUSE M, ZYROMSKA A, et al. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis [J]. Radiother Oncol, 2007, 82(1):96-104.
48. OZA AM. A phase II study or tensirolimus (CCI-779) in patients with metastatic and/or locally recurrent endometrial cancer [J]. Proc 17th Symp Mol Targets Cancer Thera, 2005, 197:269.
49. AMATO RJ, MISELLATI A, KHAN M, et al. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma (MRCC) [J]. J Clin Oncol, 2006, 24:4530.
50. JOHNSTON PB, ANSELL SM, COLGAN JP, et al. Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma [J]. J Clin Oncol, 2007, 25:8055.
51. CHANG SM, WEN P, CLOUGHESY T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme [J]. Invest New Drugs, 2005, 23(4):357-361.
52. MOHI MG, BOULTON C, GU TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs [J]. PNAS, 2004, 101(9):3130-3135.
53. HENDRIK S, GUBA M, KOEHL GE, et al. Blockage of 2-Deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-Fluorouracil therapy [J]. Clin Cancer Res, 2004, 10:1843-1852.
54. LIU LZ, ZHOU XD, QIAN GS, et al. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70s6k1 pathway [J]. Cancer Res, 2007, 67:6325-6332.
55. LU CH, WYSZOMIERSKI SL, TSENG LM, et al. Preclinical testing of clinically applicable strateies for overcoming trastuzumab resistance caused by PTEN deficiency [J]. Clin Cancer Res, 2007, 13:5883-5888.
56. KOKUBO Y, GEMMA A, NORO R, et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA) [J]. Br J Cancer, 2005, 92:1711-1719.